Editas Medicine Inc

+0.65 (+3.59%)
Earnings Announcements

Editas Medicine Reports Q2 Loss Per Share $0.78

Published: 08/03/2022 10:52 GMT
Editas Medicine Inc (EDIT) - Q2 Loss per Share $0.78.
Cash, Cash Equivalents, and Marketable Securities As of June 30, 2022, Were $527.6 Million.
Expects Existing Cash, Cash Equivalents Enable It to Fund Its Operating Expenses and Capital Expenditures Into 2024.
Qtrly Loss per Share $0.78.
Q2 Earnings per Share View $-0.82 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $4.73 Million
Adjusted EPS is expected to be -$0.85

Next Quarter Revenue Guidance is expected to be $4.7 Million
Next Quarter EPS Guidance is expected to be -$0.89

More details on our Analysts Page.